Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 19:30:51 13/02/2026 +03			5-day change	1st Jan Change
360.00 ^CHF	+0.08%		+1.01%	+9.69%

02-13	Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates	MT
02-10	ROCHE HOLDINGS AG : Barclays keeps its Buy rating	ZD

BGI Genomics, Roche roll out diagnostic tests for Alzheimer's in China

Published on 01/15/2026 at 08:05 am +03

Reuters

Latest news about Roche Holding AG

02-13	Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates	MT
02-10	ROCHE HOLDINGS AG : Barclays keeps its Buy rating	ZD
02-10	Swiss stocks - Factors to watch on February 10	RE
02-09	Roche Kept at Buy as BofA Notes 'Solid' Efficacy Data for Multiple Sclerosis Drug	MT
02-09	Avacta appoints new chief scientific officer, plans clinical trials	AN
02-09	ROCHE HOLDINGS AG : JP Morgan sticks Neutral	ZD
02-09	There is still plenty of value in the old economy
02-09	Avacta Therapeutics Announces Executive Changes	CI
02-09	Roche's fenebrutinib reduces disability progression in PPMS	RE
02-08	Roche's Investigational Drug Trial Shows Reduction in Progression of Multiple Sclerosis	MT
02-06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
02-06	Japan's Nikkei rallies on earnings in unsteady trade before Sunday election	RE
02-06	Japanese drugmakers slump after Trump unveils discount drug website	RE
02-05	ChemoMetec, Roche Diagnostics to Explore Bioprocess Monitoring Technology Collaboration	MT
02-04	Stadler Rail AG Announces Board Resignations	CI

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

03-03 - UBS European Healthcare Conference

More about the company